FDMT Q4 2024 Earnings — 4D Molecular Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FDMT4D Molecular Therapeutics, Inc.

$468M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1,000+105.3% YoY

Gross Profit

-$2M-178300.0% margin

Operating Income

-$56M-5611700.0% margin

Net Income

-$50M-4967100.0% margin

EPS (Diluted)

$-0.90

QoQ Revenue Growth

-66.7%

Cash Flow

Operating Cash Flow

-$46M

Free Cash Flow

-$47M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$560M

Total Liabilities

$50M

Stockholders' Equity

$511M

Cash & Equivalents

$149M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1,000	-$19,000	+105.3%
Gross Profit	-$2M	-$26M	+93.2%
Operating Income	-$56M	-$37M	-53.1%
Net Income	-$50M	-$32M	-53.9%

Revenue Segments

Collaboration And License Revenue

$1,000100%

Geographic Segments

UNITED STATES

$6,000100%